|
|
|
| Short and Long-term Clinical Efficacy of Montelukast Sodium in the Treatment of Cough Variant Asthma and the Effect on Serum Inflammatory Factors in Children |
| CHEN Xiujin, et al |
| Jianyang Maternal and Child Health Care Center,Sichuan Jianyang 641400, China |
|
|
|
|
Abstract Objective: To investigate the short and long- term clinical efficacy of montelukast sodium in the treatment of cough variant asthma and the effects on serum levels of tumor necrosis factor -α (TNF-α), interleukin-8 (IL-8), interleukin-10 (IL-10), and immune globulin E (IgE) in children. Methods: Totally 80 eligible children were selected, and randomly divided into observation group and control group, with 40 children in each group. Both groups were given conventional therapies, and beclometasone dipropionate inhalation aerosol was used additionally to the control group, while montelukast sodium chewable tablets was used additionally to the observation group, both used successively for 3 months. The clinical efficacy was assessed, and the serum levels of TNF-α, IL-8, IL-10, and IgE were determined before and after treatment. Results: In the observation group, 21 children were clinically controlled, of which 9 were responsive to the therapy excellently, 7 were responsive to the therapy, and 3 were unresponsive to the therapy,so the overall response rate was 75.00%; while in the control group, 13 children were clinically controlled, of which 8 were responsive to the therapy excellently, 13 were responsive to the therapy, and 6 were unresponsive to the therapy, so the overall response rate was 52.50%. The differences were statistically significant (P<0.05). The disappearance time of common symptoms such as cough, angina, and itching throat in the observation group were significantly shorter than those in the control group (P<0.05). Before the treatment, the serum level of TNF-α, IL-8, IL-10, and IgE were similar in two groups, the difference was statistically insignificant (P >0.05); After treatment, the serum level of TNF-α, IL-8, IL-10, and IgE were significantly improved in both groups compared with those before treatment, while the improving extents in the observation group were greater than those in the control group, the difference was statistically significant (P<0.05). 1 year after the treatment, totally 7 children of the observation group experienced relapse and the relapse rate was 17.50%; while totally 14 children experienced relapse and the relapse rate was 35.00%; and the difference was statistically significant (P<0.05). Conclusion: In the treatment of cough variant asthma in children, Montelukast sodium has good short-term clinical efficacy, and can shorten the symptomatic improvement time, lighten the inflammatory reactions, and reduce the long-term relapse rate.
|
|
|
|
|
|
[1] 熊凡.开瑞坦联合孟鲁司特治疗小儿咳嗽变异性哮喘的效果观察[J].临床合理用药杂志,2014,7(10):41~42.
[2] 殷华克.布地奈德联合孟鲁司特钠治疗小儿咳嗽变异性哮喘的效果观察[J].临床医学工程,2015,22(1):55~56.
[3] 蔡畅,周美茜,李玉苹,等.支气管哮喘患者白三烯基因多态性与抗白三烯治疗的相关性研究[J].中华结核和呼吸杂志,2011,34(5):362~366.
[4] 中华医学会儿科学分会呼吸学组.儿童支气管哮喘诊断与防治指南(2016年版)[J].中华儿科杂志,2016,54(3):167~181.
[5] Matsumoto H,Tabuena RP,Niimi A,et al.Cough triggers and their pathophysiology in patients with prolonged or chronic cough[J].Allergology International,2012, 61(1):123~132.
[6] 朱玲.布地奈德吸入治疗儿童CVA的疗效及其对患儿血清IgE的影响[J].重庆医学,2013,42(15):1794~1795.
[7] 周世林.两药联合治疗小儿咳嗽变异性哮喘的疗效观察[J].临床肺科杂志,2015,20(1):162~163.
[8] 丁涛,张士辉.孟鲁司特钠联合布地奈德治疗小儿咳嗽变异性哮喘的临床疗效和安全性评价[J].医学综述,2015,23(14):2637~2638,2641.
[9] 张灵芳,凌杰.儿童咳嗽变异性哮喘治疗前后血清超敏C应蛋白白细胞介素-10和肿瘤坏死因子-α水平的变化[J].中国药物与临床,2014,14(5):642~643. |
| [1] |
. [J]. 河北医学, 2017, 23(5): 783-786. |
|
|
|
|
2017, Vol. 23 
